the aid library

LIST OPTIONS

Filter

1018

Sort by:

Direction:

Download (668)

View PDF (661)

WASH and the Neglected Tropical Diseases

Ogden, S., Gallo, K., Davis, S., et al Sightsavers, Department for International Development, The International Trachoma Initiative , et al. (2013) C2

Download (831)

View PDF (1728)

Guidelines for the Management of Tuberculosis, Human Immunodeficiency Virus and Sexually-Transmitted Infections in Correctional facilities 2013

Department of Health, Republic of South Africa (2013) C1

The guidelines acknowledge that overcrowding, unhygienic conditions and high inmate turn over contribute to the spread of infectious diseases within correctional facilities. The document states that voluntary HIV counselling and testing must be offered to all inmates when they enter facilities, duri... more

Download (693)

View PDF (785)

Water, Sanitation and Hygiene (WASH) in Schools

World Health Organization (WHO) (2012) C_WHO

A companion to the Child Friendly Schools Manual
WASH in Schools aims to improve the health and learning performance of school-aged children – and, by extension, that of their families – by reducing the incidence of water and sanitation-related diseases. Every child friendly school r... more

Download (408)

View PDF (3684)

AIDSFree Project Monitoring and Evaluation Indicators Progress Report October 1, 2015 - March 31, 2016

AIDSFree Project (2016) C1

The long-term goal of AIDSFree is to improve the quality and effectiveness of high-impact, evidence-informed HIV and AIDS interventions. This semiannual performance report (SAPR) summarizes AIDSFree's achievements for the period October 1, 2015–March 31, 2016

Download (159)

View PDF (268)

HIV drug resistance patterns in pregnant women using next generation sequence in Mozambique

Rupérez et al. (2018) CC

This study aimed to understand the patterns of HIV drug resistance in pregnant women in Mozambique. This might help in tailoring optimal regimens for prevention of mother to child transmission of HIV (pMTCT) and antenatal care.

Download (405)

View PDF (783)

Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies

Alipanah N, Jarlsberg L et al. (2018) CC

We systematically reviewed Medline as well as the references of published review articles for relevant studies of adherence to multidrug treatment of both drug-susceptible and drug-resistant TB through February 3, 2018. We included randomized controlled trials (RCTs) as well as prospective and retro... more

Download (229)

View PDF (311)

Measuring Health and Disability - Manual for WHO Disability Assessment Schedule (WHODAS 2.0)

Üstün, T.B., Kostanjsek, N., Chatterji, S. & Rehm, J. WHO (2010) C_WHO

This manual summarizes the methodology used to develop WHODAS 2.0 and the findings obtained when the schedule was applied to certain areas of general health, including mental and neurological disorders. The manual will be useful to any researcher or clinician wishing to use WHODAS 2.0 in their prac... more

Download (882)

View PDF (1675)

HIV/AIDS/STI Surveillance Report

Ministry of Health, Tanzania (2014) C1

Please download the latest report from the official website: http://www.nacp.go.tz/site/publications/epidemiology-and-research-coordination

Download (616)

View PDF (1258)

Technology and Market Landscape Hepatitis C Medicines, August 2017
recommended

A.Hill, T. Swan and K.Timmermans World Health Organisation (WHO); UNITAID (2017) C_WHO

Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi- nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim- i... more

Download (234)

View PDF (152)

WHO manual for HIV drug resistance testing using dried blood spot specimens

World Health Organization WHO (2020) C_WHO

HIV-1 drug resistance (HIVDR) genotyping is an essential component of the WHO global HIVDR surveillance strategy. Plasma “gold standard” specimen type for HIVDR genotyping, but its use may not be feasible in rural, remote areas in low- and middle-income countries, since preparing and storing it ... more

Download (229)

View PDF (261)

Accelerating access to hepatitis C diagnostics and treatment

World Health Organization WHO (2021) C2

Overcoming barriers in low- and middle-income countries For the first time, this year’s report includes information on hepatitis C diagnostics. With a focus on selected countries with diverse HCV epidemics, the report provides updates on the various dimensions of access to HCV diagnostics and pha... more

Download (125)

View PDF (187)

Operational public health considerations for the prevention and control of infectious diseases in the context of Russia’s aggression towards Ukraine
recommended

European Centre for Disease Prevention and Control ECDC; WHO Europe (2022) C1

8 March 2022 A very large number of people from Ukraine are fleeing the country and entering the European Union (EU) countries bordering Ukraine (Hungary, Poland, Romania, Slovakia) and the EU-neighbourhood country of the Republic of Moldova. Those fleeing Ukraine - mainly women and children - are ... more

Download (80)

View PDF (129)

Guidelines for Case-Finding, Diagnosis, and Public Health Response in South Africa

Bham, A.; J. Bhiman, F. Bongweni et al. National Department of Health South Africa (2020) CC

In the light of the transmissibility of coronaviruses, and the global experience with MERS-CoV (ongoing) and SARS in 2003 which were also caused by coronaviruses, South African authorities have compiled this guideline document to support surveillance, case finding, diagnosis, management and public h... more

Download (134)

View PDF (151)

Using recency assays for HIV surveillance: 2022 technical guidance

World Health Organization WHO (2022) C_WHO

Recency assays use one or more biomarkers to identify whether HIV infection in a person is recent (usually within a year or less) or longstanding. Recency assays have been used to estimate incidence in representative cross-sectional surveys and in epidemiological studies to better understand the pat... more

Download (142)

View PDF (173)

Human and dog rabies prevention and control

World Health Organization WHO; Bill & Melinda Gates Foundation (2009) C_WHO

Report of the WHO/Bill & Melinda Gates Foundation Consultation. The Consultation was organized back-to-back with the first annual meeting of the International Coordinating Group of the BMGF-funded project for human and dog rabies elimination in developing countries, held at WHO headquarters, Geneva,... more

Download (102)

View PDF (632)

Serious adverse events following treatment of visceral leishmaniasis: A systematic review and meta-analysis

Singh-Phulgenda, S., Dahal, P., Ngu, R. et al. PLOS Neglected Tropical Diseases (2021) C1

Despite a historical association with poor tolerability, a comprehensive review on safety of antileishmanial chemotherapies is lacking. We carried out an update of a previous systematic review of all published clinical trials in visceral leishmaniasis (VL) from 1980 to 2019 to document any reported ... more

Download (108)

View PDF (210)

The Control of Neglected Zoonotic Diseases - Community-based interventions for prevention and control

World Health Organization WHO (2010) C_WHO

Report of the third conference organized with ICONZ, DFID-RIU, Gates Foundation, SOS, EU, TDR and FAO with the participation of ILRI and OIE WHO headquarters, Geneva, Switzerland 23–24 November 2010 In this report we have tried to present the various issues, problems and challenges that ... more

Download (245)

View PDF (329)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (26)

View PDF (20)

Cardiovascular diseases in Africa in the twenty-first century: Gaps and priorities going forward

Minja, N.W.; Nakagaayi, D.; Aliku, T. et al. Frontiers in Cardiovascular Medicine (2022) CC

In 2015, the United Nations set important targets to reduce premature cardiovascular disease (CVD) deaths by 33% by 2030. Africa disproportionately bears the brunt of CVD burden and has one of the highest risks of dying from non-communicable diseases (NCDs) worldwide. There is currently an epide...miological transition on the continent, where NCDs is projected to outpace communicable diseases within the current decade. Unchecked increases in CVD risk factors have contributed to the growing burden of three major CVDs—hypertension, cardiomyopathies, and atherosclerotic diseasesleading to devastating rates of stroke and heart failure. The highest age standardized disability-adjusted life years (DALYs) due to hypertensive heart disease (HHD) were recorded in Africa. The contributory causes of heart failure are changing—whilst HHD and cardiomyopathies still dominate, ischemic heart disease is rapidly becoming a significant contributor, whilst rheumatic heart disease (RHD) has shown a gradual decline. In a continent where health systems are traditionally geared toward addressing communicable diseases, several gaps exist to adequately meet the growing demand imposed by CVDs. Among these, high-quality research to inform interventions, underfunded health systems with high out-of-pocket costs, limited accessibility and affordability of essential medicines, CVD preventive services, and skill shortages. Overall, the African continent progress toward a third reduction in premature mortality come 2030 is lagging behind. More can be done in the arena of effective policy implementation for risk factor reduction and CVD prevention, increasing health financing and focusing on strengthening primary health care services for prevention and treatment of CVDs, whilst ensuring availability and affordability of quality medicines. Further, investing in systematic country data collection and research outputs will improve the accuracy of the burden of disease data and inform policy adoption on interventions. This review summarizes the current CVD burden, important gaps in cardiovascular medicine in Africa, and further highlights priority areas where efforts could be intensified in the next decade with potential to improve the current rate of progress toward achieving a 33% reduction in CVD mortality. more

Download (4)

View PDF (35)

Hearts - D: Diagnosis and Management of Type 2 Diabetes 2020

World Health Organization WHO; International Diabetes Federation (2020) C_WHO

Diabetes mellitus, commonly known as diabetes, is a group of metabolic disorders characterized by the presence of hyperglycaemia in the absence of treatment. The heterogeneous aetiopathology includes defects in insulin secretion, insulin action, or both. The long-term specific complications of diabe... more

Technology and Market Landscape Hepatitis C Medicines, August 2017 recommended

Operational public health considerations for the prevention and control of infectious diseases in the context of Russia’s aggression towards Ukraine recommended

Technology and Market Landscape Hepatitis C Medicines, August 2017
recommended

Operational public health considerations for the prevention and control of infectious diseases in the context of Russia’s aggression towards Ukraine
recommended